As we previously have reported, Gal3 is primarily expressed and released by reactive microglia and has been implicated in multiple aspects of AD pathology, ranging from amyloid aggregation to neuroinflammatory signaling, along with increased CSF levels in AD patients (Burguillos et al., 2015; Boza-Serrano et al., 2019; Tao et al., 2020). This evidence concerns the gene LGALS3 and Alzheimer disease.